Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Asymmetric Hydrogenation Catalysis. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN119431279B reveals a novel Ir-catalyzed asymmetric hydrogenation route for chiral cyclic ethers, offering superior purity and cost-effective manufacturing for pharmaceutical intermediates.
Patent CN105017150A details a palladium-catalyzed asymmetric hydrogenation method for high-purity chiral exocyclic amines, offering significant supply chain and cost advantages.
Advanced patent CN110590606A details efficient asymmetric hydrogenation and enzymatic reduction for high-purity pharmaceutical intermediates, ensuring cost-effective and scalable supply chain solutions.
Patent CN1491951A reveals novel asymmetric hydrogenation and microbial routes for high-purity azepine intermediates, offering significant cost reduction in pharmaceutical manufacturing.
Discover advanced catalytic methods for pyrimidylcyclopentane intermediates. Enhance purity and reduce costs in AKT inhibitor manufacturing with our scalable solutions.
Patent CN1926083B details a novel ruthenium-catalyzed asymmetric hydrogenation method for producing high-purity optically active alcohols with superior stereoselectivity and yield.
Patent CN103420908A reveals a high-yield asymmetric hydrogenation route for Montelukast intermediates, offering significant cost reduction and supply chain reliability for API manufacturers.
Patent CN109942514A reveals efficient Ir-catalyzed route for Atazanavir intermediate. Enables cost reduction in API manufacturing and reliable supply chain continuity.
Novel iron-catalyzed asymmetric hydrogenation using chiral quinoline imidazoline ligands offers high enantioselectivity and cost-effective alternatives to noble metals for pharmaceutical intermediates.
Patent CN111333573A details a robust asymmetric hydrogenation process for dextromethorphan intermediates, offering superior enantioselectivity and scalable manufacturing advantages.
Patent CN102264672A details a scalable route to chiral phenols using Ru-catalyzed transfer hydrogenation, offering cost reduction and high purity for pharmaceutical manufacturing.
Patent CN112824421A reveals a robust chiral ligand synthesis route offering high enantioselectivity and TON up to 10000 for pharmaceutical manufacturing.
Patent CN111574487B details a novel asymmetric hydrogenation method for producing high-purity chiral dihydroisoflavones, offering significant supply chain and cost advantages.
Patent CN102984945B details a high-yield asymmetric hydrogenation process for Ramipril and Perindopril intermediates, offering significant cost and purity advantages for pharmaceutical supply chains.
Patent CN111690009A discloses novel Co/Fe complexes for high-ee hydrogenation of alpha-silyl styrenes, offering cost-effective pharma intermediate synthesis.
Patent CN113980017A reveals a high-yield asymmetric hydrogenation route for tetrahydro-13-methyl berberine derivatives, offering significant cost reduction and scalability for pharmaceutical manufacturing.
Patent CN112409235A details a Rh-catalyzed asymmetric hydrogenation route for chiral 4-halogenated tryptophan derivatives with 99.9% ee, offering a scalable solution for API intermediates.
Novel Rh-catalyzed asymmetric hydrogenation avoids resolution, boosting yield to 42.55% for reliable API intermediate supply.
Novel iron-catalyzed asymmetric hydrogenation technology using chiral quinoline imidazoline ligands. Reduces noble metal dependency for high-purity pharmaceutical intermediates.
Reduce supply chain risks with metal-free deracemization process. 90%+ yield, 95% ee, and scalable production for chiral alcohol intermediates.